Sanofi
- SEC CIK
- 0001121404
- Latest filing
- Jul 28, 2026
The latest 13F from Sanofi covers Q2 2026 (filed Jul 28, 2026): 10 long positions worth $534.0M. The top 10 holdings make up 100.0% of the portfolio, and the largest is MeiraGTx Holdings plc (MGTX) at 30.9%. Livermore has 7 filings on Form 13F from this institution, going back to Q4 2024.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 2
- Est. +$53.8M
- Added
- 0
- Reduced
- 0
- Sold out
- 1
- Est. −$2.51M
Top 5 holdings
Share of this quarter's portfolio value
Biggest buys
New and added positions, by estimated amount bought
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $534.0M
- +$198.1M (+59.0%) vs. prior quarter
- Positions
- 10
- +1 vs. prior quarter
- Top 10 concentration
- 100.0%
- Top 10 as share of value
- Turnover
- 0.6%
- Q2 2026, one quarter
- Average holding period
- 5.7 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2024), so positions held before then are understated.
13F filings by quarter
7 quarters, going back to Q4 2024. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $534.0M (Q2 2026)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 28, 2026 | 10 | $534.0M | MGTXINBXNVAX | vs. Q1 2026 | SEC |
| Q1 2026 | May 7, 2026 | 9 | $336.0M | MGTXINBXNVAX | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 11, 2026 | 8 | $310.4M | MGTXINBXNVAX | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 4, 2025 | 9 | $260.4M | MGTXNVAXINBX | vs. Q2 2025 | SEC |
| Q2 2025 | Jul 29, 2025 | 10 | $175.7M | MGTXNVAXANAB | vs. Q1 2025 | SEC |
| Q1 2025 | May 6, 2025 | 9 | $165.9M | MGTXNVAXINBX | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 14, 2025 | 9 | $174.4M | MGTXNVAXINBX | – | SEC |
13D and 13G filings
Companies where Sanofi reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
2 companies, largest stake first.
Latest filings
8 filings on file made by Sanofi or listing it as a reporting person, newest first.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| AGMBAgomAb Therapeutics NV | May 6, 20266:00 AM ET | 13G | 5.71%2.78M shares | New | Mar 31, 2026 | SEC |
| IPHAInnate Pharma SA | Apr 29, 20256:48 PM ET | 13G/A | 9.05%8.35M shares | 0.00 ppfrom 9.05% | Apr 23, 2025 | SEC |
| IPHAInnate Pharma SA | Apr 29, 20252:08 PM ET | 13G | 9.05%8.35M shares | New | Apr 23, 2025 | SEC |
| ICVXIcosavax, Inc. | Feb 8, 2022 | 13GOld format | – | New | – | SEC |
| Translate Bio, Inc. | Aug 12, 2021 | 13DOld format | – | – | – | SEC |
| LVTXLAVA Therapeutics NV | Mar 31, 202111:19 AM ET | 13GOld format | – | New | – | SEC |
| RVMDRevolution Medicines, Inc. | Feb 11, 202110:46 AM ET | 13GOld format | – | New | – | SEC |
| Translate Bio, Inc. | Feb 4, 2021 | 13GOld format | – | New | – | SEC |